Penn Medicine Provider
Endocrine and Oncologic Surgery
Mark Stephen Etherington, MD
Accepting new patients
Sees patients age 18 and up
Penn Endocrine and Oncologic Surgery Washington Square 20th Floor
Schedule onlineCall 215-829-8461

About me

  • Assistant Professor of Surgery at the Hospital of the University of Pennsylvania

I am a gastrointestinal and hepatopancreatobiliary cancer surgeon with a focus on robotic, minimally invasive surgical techniques.

I specialize in the surgical treatment of abdominal cancers including pancreatic cancer, primary and metastatic tumors of the liver, bile duct tumors, stomach cancer, small bowel cancer, neuroendocrine tumors, GISTs, and retroperitoneal sarcomas. I perform minimally invasive, robotic Whipple procedure for the treatment of pancreatic cancer.

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: University of Pittsburgh Medical Center

Insurance accepted

My Locations

Penn Endocrine and Oncologic Surgery Washington Square 20th Floor

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Etherington is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Etherington MS, Gajdos C. Invited commentary on "Parenchymal-sparing hepatectomy vs single-stage major hepatectomy for bilateral colorectal liver metastases: a higher rate of microscopically positive margins is not associated with increased local recurrence after parenchymal-sparing hepatectomy. Is it time to rethink surgical approaches to multifocal bilateral colorectal liver metastasis?" , J Gastrointest Surg, 29: 2025,102116

Etherington MS, Karakousis GC. Circulating Micro-RNA as a Predictive Biomarker for Radiation Response in Pancreas Cancer , Ann Surg Oncol: 2025

Etherington MS, Geller DA Minimally invasive vs. open liver resections for hepatocellular carcinoma and colorectal cancer liver metastases , Surgery: Evidence Based Practice, 2d Edition: 2024 (in press)

Etherington MS, Handzel R, Ongchin M, Choudry MH, Tohme ST, Paniccia A, Lee KK, Zureikat A, Geller DA Remnant completion cholecystectomy is on the rise: Don't three-putt it , HPB (Oxford), 26(8): 2024,1072-1074

Etherington MS, O’Sullivan R, Paniccia A, Brand RE, McGrath K, Slivka A, Singhi AD, Zureikat AH Genomic profiling of pancreatic neuroendocrine tumors defines clinically relevant prognostic markers , HPB, 26(2): 2024,S613-S614

Etherington MS, Handzel R, Ongchin M, Choudry MH, Tohme ST, Paniccia A, Lee KK, Zureikat A, Geller DA Remnant cholecystectomy: A twenty year institutional experience , HPB, 26(2): 2024,S645

Wach MM, Washburn LA, Alvikas J, Qu LT, Zhang M, Etherington MS, Rieser C, Haykal T, Pingpank JF, Zureikat AH, Geller DA, Hoehn RS, Tohme S Combined hepatic resection and ablation for high burden of colorectal liver metastases demonstrates safety and durable survival , HPB (Oxford), 26(3): 2024,362-369

Lo WM, Dogeas E, Etherington MS, Ferrone C, Nebbia M, Cleary S, Pery R, Steel JL, Tohme ST, Geller DA Long-term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma , Journal of Surgical Oncology, 129(3): 2024,568-573

Etherington MS, Hanna AN, Medina BD, Liu M, Tieniber AD, Kwak HV, Tardy KJ, Levin L, Do KJ, Rossi F, Zeng S, DeMatteo RP Tyrosine kinase inhibition activates intratumoral gamma delta T cells in gastrointestinal stromal tumor , Cancer Immunology Research, 12(1): 2024,107-119

Etherington MS, Tohme ST, Ongchin M, Geller DA Remnant completion cholecystectomy at a single institution over 20 years: Don't three-putt it , Journal of the American College of Surgeons, 23(5 Suppl 1): 2023,S301-S302